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Introduction
Patients with glioblastoma multiforme (GM), the most frequent intracranial tumor in adults, 1 rarely survive greater than 1 year after diagnosis despite surgical resection and chemotherapy. 2 The grim prognosis coupled with the significant morbidity of current treatment has sparked interest in the development of gene transfer techniques to improve patient outcome. One vector system under investigation in rodent and human studies is the recombinant adenovirus. [3] [4] [5] [6] Adenovirus-mediated transfer of cytotoxic gene products such as herpes simplex type I thymidine kinase (HSVtk) to tumor models of GM, followed by systemic treatment with the prodrug ganciclovir (GCV) has shown promising results in rodents. In rat and mice models, tumor growth rates are significantly reduced and survival is prolonged after transfer of HSVtk sequences and administration of GCV. [3] [4] [5] However, after the initial infection with replication-impaired adenovirus encoding HSVtk, exposure to GCV initiates a limited therapeutic response since the cells expressing the gene product are killed. To improve therapy, the tumor needs to be redosed with the vector followed by additional GCV treatment.
The host immune response following adenovirus delivery is robust in all tissues, including the brain. 7, 8 In tumor-bearing hosts, the response may be beneficial for therapy but detrimental to subsequent vector delivery. The T cell response to cells infected with virus may enhance killing of tumor cells, but B cell activation causes a neutralizing antibody response which limits redosing. 9 An initial infection with lower vector titers (often not efficacious) or infection with virus formulated to reduce its antigenicity would allow for redosing.
In recent years, biodegradable microspheres have been successfully used to formulate drugs for altered immunogenicity and controlled release rates in multiple tissues. [10] [11] [12] Although several types of polymers have been used in the manufacture of microspheres, copolymers of lactide and glycolide (PLGA) are the most common. PLGA is relatively nontoxic, and in vitro and in vivo degradation occurs by acid or base catalyzed hydrolysis to release lactic and glycolic acid. 13 In this study, we demonstrate that recombinant adenovirus is amenable to formulation in a PLGA polymer preparation, and that the resulting product elicits a diminished immune response from the host. We also show that PLGA-formulated recombinant adenovirus is less susceptible to inactivation by neutralizing antibodies in vitro.
Results
Previous reports have shown reduction in tumor growth rate of 9L-gliosarcoma cells in rat brain upon intra-tumoral inoculation with recombinant adenovirus expressing HSVtk (Adtk) and GCV therapy. [3] [4] [5] However, the effect was modest. We found that subsequent dosing did not further slow tumor growth (Figure 1a) . Although others have shown that neutralizing antibodies are present following recombinant adenovirus-mediated gene transfer to lung (Figure 1b) . Although this experiment cannot discount a contribution from cytotoxic T lymphocytes, we hypothesize that the presence of neutralizing antibodies contributed significantly to the reduction in gene transfer efficiency and hence transgene expression, after 5 days (Figure 1b) .
Although many proteins have been successfully encapsulated into polymers with subsequent alterations in antigenic profiles, 17 polymer preparations of biomolecules such as recombinant adenovirus have not been investigated. We tested if recombinant Ad could be encapsulated into poly-lactic glycolic acid (PLGA) using a double emulsion technique, 17, 18 and if this formulation could allow for transduction of cells in vitro. Ad␤gal was radiolabeled with 35 S-methionine and purified to a final concentration of 1 × 10 12 particles (pt)/ml. Radiolabeled virus was added to PLGA dissolved in methylene chloride while vortexing and spheres formed and harvested as described in Materials and methods. Increasing the volume of input virus did not significantly change the yield of virus encapsulated, which ranged from 6.7 to 9.2% for 50 to 150 l of input virus, respectively (Figure 2a ). The number of viral particles encapsulated was confirmed by DNA slot blot analysis after dissolution of the spheres (data not shown). Approximately 14 to 45% of the virus encapsulated could be released from the harvested spheres, depending on the input volume during the encapsulation (Figure 2b ). Although virus was released for more than 200 h, 70 to 90% was shed within the first 100 h.
Particle size of PLGA microspheres is largely influenced by the rate of vortexing and the volume of the inner water and organic phases during the encapsulation. 19 When the volume of aqueous solution (containing adenovirus) added to PLGA in methylene chloride was less than 100 l the microspheres formed by the encapsulation of recombinant adenovirus were 10 to 100 m in size as determined by scanning electron microscopy (SEM, Figure 2c ). Larger input volumes resulted in significant heterogeneity in particle shape and size (data not shown). For these reasons we used microspheres formed from 50 l input volume of virus for all subsequent studies. Electron photomicrographs of thin sections prepared for transmission electron microscopy (TEM) demonstrate clearly that virus is associated with the polymer (Figure 2d ).
We tested for viability of adenovirus released from microspheres by assay for ␤-galactosidase activity or by HSVtk-mediated killing using Ad␤gal or Adtk, respectively. Encapsulated Ad␤gal (EnAd␤gal) retained viability and was able to transduce cells in vitro as measured by ␤-galactosidase histochemistry (Figure 3a) . Most of the viable virus is released before 50 h, with additional release over the next 150 h. This profile is similar to the release of radioactive virus noted in Figure 2b .
9L gliosarcoma cells were exposed to increasing concentrations (pt/ml) of free or encapsulated Adtk (EnAdtk) and subsequently exposed to GCV. As shown in Figure 3b , EnAdtk decreased cell survival in a dosedependent manner. A dose of 2.5 × 10 4 particles per cell (release dose) of EnAdtk resulted in a 16% cell kill, while approximately 20% of cells were killed after exposure to 5 × 10 4 particles per cell of Adtk. These results suggest that the ratio of infectious virions to particles has not been significantly altered by encapsulation. Together, the data show that recombinant adenovirus can be encapsulated in PLGA with retention of the capacity to transduce cells.
Figure 2 Recombinant adenovirus can be encapsulated in PLGA. (a) Radiolabeled adenovirus was encapsulated in PLGA (Materials and methods) and the amount encapsulated determined using scintillation counting of aliquots dissolved in methylene chloride. Increasing the volume of input virus did not significantly improve the amount encapsulated. (b) The amount of virus released from spheres increases with increasing input volumes. Fifty, 100 or 150 l of radiolabeled virus was encapsulated and the percentage of virus released determined as described (Materials and methods). (c) Ad␤gal was encapsulated and spheres harvested and examined by SEM. A representative photomicrograph of the spheres demonstrates a range of sizes (diameters
PLGA-encapsulated antigens with a particle size greater than 10 m are less susceptible to phagocytosis by dendritic cells or macrophages and as such are less immunogenic. 20 We tested if PLGA-encapsulated adenovirus was less immunogenic in vivo. PLGAencapsulated adenovirus, and an equivalent 'release dose' of non-encapsulated adenovirus (of 1.5 × 10 8 pt of EnAd␤gal or Ad␤gal) were injected into mice subcutaneously every 14 days. Serum anti-Ad levels were measured 12 days after each inoculation. Figure 4a shows that anti-Ad IgG levels increased significantly with each dose of Ad␤gal. Significant antibody levels in EnAd␤gal injected mice did not develop until after the third dose, and once present, were 45-fold lower than anti-Ad titers from Ad␤gal-injected mice (Figure 4a ). Neutralizing titers in blood from EnAd␤gal injected mice were also quite low (14 ± 8.3), even after three injections of encapsulated virus. In contrast, titers from Ad␤gal injected mice were significantly elevated after two injections (183 ± 46), and approximately 30-fold higher than EnAd␤gal injected mice (427 ± 74 versus 14 ± 8.3) after the third virus inoculation (Figure 4a ). The process of encapsulation in polymer preparations has the potential to mask the adenovirus from circulating antibodies in vivo by effectively embedding the antigen (adenovirus) into the polymer. We used an in vitro model to determine if encapsulated adenovirus may be less susceptible to inactivation by neutralizing antibodies. EnAd␤gal or Ad␤gal was incubated in rat serum containing neutralizing antibodies to Ad5, and the mix added to HeLa cells. Cells were assayed by ␤-galactosidase histochemistry (data not shown) or by ␤-galactosidase activity assay 48 h later. A representative experiment is shown in Figure 4b . Although prior incubation of Ad␤gal with neutralizing serum, diluted 1/100 or 1/500, inhibited gene transfer by greater than 99% at both dilutions, separate preparations of encapsulated adenovirus retained 27-50% and 62-65% control activity at both dilutions, respectively. We examined whether inactivation of the antibody during culturing and later release of encapsulated virus could account for the differences between EnAd␤gal and Ad␤gal. Anti-adenoviral serum was added every 4 h in a similar experiment with no change from previous results (data not shown). Further, TEM examination of HeLa cells cultured on Millicell supports and incubated with EnAd␤gal suggests that at least a portion of virus is released to the cell and not into the surrounding media (Figure 4c) , making neutralization by anti-Ad antibodies less likely.
Discussion
Our results are encouraging as they indicate that formulation of adenovirus vectors is feasible; recombinant adenovirus can be formulated in a polymer preparation of PLGA with retention of bioactivity. However, our data also indicate that efficacy testing of PLGA-formulated adenovirus will require improvements in formulation methods.
We noted an increase in the amount of virus released by increasing the inner water volume from 50 to 150 l with no change in encapsulation efficiency (Figure 1 ). Changing the ratio of lactide:glycolide, the MW of the polymer, and sieving to achieve uniformity of sphere size, may allow further optimization of early or late release profiles. 18, 20 Alternatively, a mix of spheres with different release kinetics may prove useful for achieving transduction both immediately and hours to days later. Prolonged release of virus for days to months would have application to many CNS disorders where repeated intracranial delivery is not feasible and the blood-brain barrier inhibits systemic delivery of current viral vectors.
Macrophages, dendritic cells, microglia and B cells phagocytose or endocytose antigen and present foreign peptides to circulating lymphocytes. This results in production of pro-inflammatory cytokines by the antigenpresenting cells and B and T cell activation. 21, 22 Particles greater than 10 m in size are less susceptible to phagocytosis and endocytosis. In studies with PLGA-encapsulated antigens for vaccine development, particles greater than 10 m were less antigenic. 23, 24 In our studies we were able to achieve an average sphere size of 100 m with most particles greater than 10 m. Mice inoculated with EnAd␤gal showed reduced anti-adenoviral levels compared with an equivalent dose (based on yield of virus released) of non-encapsulated adenovirus. The reduced antigenicity may prove beneficial for redosing and importantly would reduce the amount of neutralizing antibodies that could sequester virus released from a slow release preparation.
In addition to the reduced antigenicity we also noted that EnAd␤gal was less susceptible to inactivation by neutralizing antibodies than unencapsulated adenovirus. Our in vitro data suggests that this is due to the close association of spheres and cells. Following in vivo implantation of EnAd␤gal, positive gene transfer is localized closely around the injection site (data not shown) further supporting this hypothesis. Because animals inoculated subcutaneously with EnAd␤gal do eventually develop an anti-adenoviral antibody response, albeit very low, reduced susceptibility of encapsulated adenovirus vectors to neutralizing antibodies in vivo should improve efficacy upon redosing.
These studies provide evidence that appropriate formulation may overcome potent neutralizing antibody responses to the viral capsid. Such an approach may be translated to other encapsidated viruses used in gene transfer protocols. cells using routine methods. 25 To label adenovirus metabolically, 293 cells were infected with 5 × 10 8 IU/15 cm plate for 20 h and then incubated in DMEM without methionine and cystine (ICN Pharmaceuticals, Costa Mesa, CA, USA) for 2 h. S-methionine (Amersham Life Sciences, Arlington Heights, IL, USA) was added (1 mCi/100 ml) for the remainder of the amplification. Cells were harvested upon evidence of cytopathic effect (30-32 h) and virus purified, desalted and diluted to a final concentration of 1 × 10 12 pt/ml 26 in 50% glycerol, 100 mg/ml BSA. The adenoviruses AdRSV␤gal and AdRSVtk contain coding sequences for nuclear targeted E. coli ␤-galactosidase (␤gal) and HSV type I thymidine kinase (tk) and have been previously described. 16, 27 They are denoted as Ad␤gal and Adtk throughout the manuscript. Adgfp was made by homologous recombination using the adenovirus shuttle plasmid pAdRSV4 28 containing the jellyfish green fluorescent protein (gfp) under control of the Rous sarcoma virus LTR and flanked 3′ with a SV40 polyadenylation signal, and ClaI/XbaI digested dl309. Plaques were scored for recombination by DNA slot blot analysis for RSV sequences and amplified. Viruses containing gfp were replaqued twice. Plaque forming units were determined by 293 cells plaque assay.
Materials and methods

particles of EnAd␤gal (release dose) or Ad␤gal at the times indicated (arrows) and blood collected 12 days after each injection for anti-Ad IgG measurements. Neutralizing titers in blood from Ad␤gal-injected mice ( ; days 26 and 40) and EnAd␤gal-injected mice (+; day 40) are also shown. Levels were determined as described in Materials and methods. (b) Encapsulated adenovirus retains approximately 30 to 60% activity following incubation with a 1/100 or 1/500 dilution of neutralizing rat serum, respectively, while nonencapsulated Ad␤gal is more than 99% inactivated at either dilution. The results from two independent encapsulations are shown. Percentage inactivation of EnAd␤gal relative to non-encapsulated Ad␤gal was repeated three times with six independent encapsulations. (c) TEM photomicrograph demonstrates virions near a sphere associated with a HeLa
Wild-type contamination was determined by plaque assay on A549 cells and by PCR for E1-containing sequences.
PLGA encapsulation of recombinant adenovirus
One milliliter 75/25 DL-PLG (MW 9400; Birmingham Polymers, Birmingham, AL, USA) in methylene chloride (20%) w/v was placed into a polypropylene tube and 50 l recombinant adenovirus (Ad␤gal or Adtk in 50% glycerol 100 mg/ml BSA) added while vortexing. The first emulsion was added to 2 ml 1% polyvinyl alcohol (average MW 30 000 to 70 000; Sigma Biochemicals, St Louis, MO, USA) in PBS with continued vortexing for 30 s. The resultant double emulsion was diluted in 100 ml 5% isopropyl alcohol with continuous stirring for 2-3 h to evaporate the methylene chloride. Spheres were harvested by gentle centrifugation at 800 g and rinsed 5 × 100 ml in PBS. Spheres were resuspended to a final volume of 1 ml in PBS and used immediately or frozen at −20°C.
35
S-radiolabeled Ad␤gal was incorporated into spheres and one-tenth of the product dissolved in methylene chloride and counted to determine yield encapsulated. The remaining product was aliquoted into 24-well tissue culture plates containing 300 l of tissue culture media and incubated at 37°C. At the indicated times, the amount of incorporated c.p.m. released into the medium was determined. Data are presented as cumulative c.p.m. released. The total number of particles incorporated were determined by DNA slot blot following isolation of input DNA from spheres by phenol/chloroform extraction.
Anti-adenoviral antibody assays
Maxisorp microtiter plates (Sybron Corporation, Rochester, NY, USA) were coated with 10 9 particles per well in 50 l 0.1 m sodium bicarbonate, pH 9.2 at 4°C for 24 to 72 h. Plates were washed in wash buffer (PBS with 0.01% Tween) and blocked with 3% BSA in PBS. After removal of blocking solution, 100 l of sample or standard dilutions were added to duplicate wells and incubated for 3 h at room temperature. Plates were washed, followed by addition of 100 l of horseradish peroxidaseconjugated secondary antibody (goat anti-mouse IgG, Fc␥ chain-specific; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Following a 1-h incubation, plates were washed and substrate solution (0.5 mg/ml O-phenylenediamine in 0.04 m NaPO 4 , 0.02 m citric acid, pH 5.0, 0.4 l/ml 30% H 2 O 2 ) added. Plates were read in a Thermomax Micro Plate Reader (Molecular Devices, Sunnyvale, CA, USA) at 490 nm following addition of 25 l 4.5 m H 2 SO 4 stop solution. Commercially available murine anti-Ad IgG (Fitzgerald Industries, Concord, MA, USA) was used as a standard.
Anti-Ad neutralization assays of plasma was done using HeLa cells cultured as described above. Twenty thousand cells per well were seeded into a 96-well culture dish. The following day, plasma samples were heat inactivated at 56°C for 30 min and diluted by two-fold series with DMEM. Ad␤gal (1.0 × 10 6 IU) was added to each sample dilution and incubated at room temperature for 20 min. Samples and controls were placed on HeLa cells in duplicate wells and incubated for 1 h at 37°C. Cells were rinsed and media added. After 24 h, cells were rinsed with PBS and ␤-galactosidase activity measured according to the manufacturer's instructions (GalactoLight Plus kit; Tropix, Bedford, MA, USA). Data are expressed as reciprocal titers of the dilution giving 50% neutralization.
Animal studies
All experiments had prior approval by accredited animal care facilities at the University of Michigan and the University of Iowa. In vivo intracranial 9L tumor doubling times were quantified from multislice T2-weighted MR images as previously described. 3, 29 Male Fischer 344 rats were intracranially implanted in the right frontal lobe region with 10 5 9L cells. In vivo MRI was initiated 10 to 12 days after implantation and performed serially on average every 2 days throughout the duration of the experiment. Adtk or Ad␤gal (25 l, concentration 10 11 pt/ml, pt:IU ratio, 100) was injected after intracranial volumes were Ͼ50 mm 3 . A second equivalent intratumoral injection of Adtk or Ad␤gal was administered 4-5 days later. Effects of viral injections on tumor growth kinetics were quantified as changes in tumor doubling times from pretreatment doubling time data. 3 This approach allowed each animal to serve as its own control since untreated intracranial 9L tumors grow exponentially until death. 29 Fischer 344 rats (Harlan Sprague Dawley Laboratories, Indianapolis, IN, USA) were used to determine the ability to redose with recombinant adenoviral vectors in the rodent brain. Rats were given intrastriatal injections of 10 8 IU of Adgfp on day 1, followed 14 days later by 10 8 IU of Ad␤gal into the same hemisphere. Control animals received PBS on day 1. Animals were anesthetized and bled retro-orbitally every 7 days until they were killed 5 days after Ad␤gal injections. Striata were harvested, homogenized and ␤-galactosidase activity measured by a Galacto-Light Plus kit (Tropix) using a luminometer (Monolight 2010; Analytical Luminescence Laboratory, Ann Arbor, MI, USA).
Eight-week-old CBA mice (Jackson Laboratories, Bar Harbor, ME, USA) were given three subcutaneous injections at 14 day intervals of 1.5 × 10 8 pt (release dose) of EnAdgfp (n = 12) or Adgfp (n = 12). Injections were given in a total volume of 375 l. Twelve days after each injection serum was collected from anesthetized mice by retro-orbital bleeding.
Electron microscopy
For scanning electron microscopy, PLGA-encapsulated virus was fixed in 2.5% glutaraldehyde in 0.1 m cacodylate buffer, pH 7.3, followed by a secondary fixation in 1% osmium tetroxide in 0.1 m cacodylate buffer for 1 h. Samples were dehydrated in increasing concentrations of ethanol. After a second 100% EtOH rinse, sample drops were placed on to poly-l-lysine-coated silicon wafers. Further dehydration was accomplished with hexamethlydisilizane (Polysciences, Warrington, PA, USA). The polymer-bearing wafers were affixed to aluminum stubs with double-sided carbon tape and sputter-coated in an Emitech K550 sputter coater with a gold/palladium target. Samples were viewed with a Hitachi S-4000 scanning electron microscope (Deerfield, IL, USA) with a field emission electron source.
For TEM of virus after PLGA encapsulation spheres were fixed overnight in 2.5% glutaraldehyde in 0.1 m cacodylate buffer, pH 7.3 followed by a secondary fixation in 1% osmium tetroxide in 0.1 m cacodylate containing 1.5% potassium ferrocyanide. Samples were dehydrated in graded acetone, infiltrated with Spurr's resin (Polysciences) and cured overnight at 70°C. Thin sections (approximately 90 nm) were cut on ReichertJung Ultracut E microtome and sections placed on 400 mesh copper grids. Samples were counterstained with 5% uranyl acetate and Reynolds lead citrate. Sections were viewed with a Hitachi H-7000 transmission electron microscope. For TEM of HeLa cells after addition of spheres, cells were fixed after an overnight incubation with EnAd␤gal in a 1:1 mixture of cell culture medium and 2.5% glutaraldehyde in 0.1 m cacodylate buffer, pH 7.2 for 5 min at 37°C. The solution was removed and replaced with 100% fixative overnight at 4°C followed by fixation in 1% osmium tetroxide in 0.1 m cacodylate buffer with 1.5% potassium ferrocyanide for 30 min at room temperature. Samples were dehydrated in graded EtOH to 100% and infiltrated with a mixture of ethanol/Eponate 12 embedding medium (Ted Pella, Redding, CA, USA) on a rotator. The Epon concentration was gradually increased to 100%. Samples were cured overnight at 60°C and 100-nm sections cut and counterstained with 5% uranyl acetate and Reynold's lead citrate and viewed on a Hitachi S-7000 transmission electron microscope.
